Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis
NCT ID: NCT01387815
Last Updated: 2019-12-05
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
662 participants
OBSERVATIONAL
2011-08-16
2018-06-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis
NCT00513370
Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE)
NCT01076192
Post-Marketing Surveillance Study of Adalimumab in Pediatric Chronic Severe Plaque Psoriasis Patients in Korea
NCT03925441
Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet
NCT00735787
Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice
NCT01202565
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Topical/Traditional Systemic Agent
Participants who initiated treatment with a new topical agent that was not used before or already being treated with topical agent and not responding, thereby requiring a change of treatment type, frequency, or dose and all participants who initiated treatment with a new systemic agent that was not used before alone or in combination with topical agents.
No interventions assigned to this group
Adalimumab
Participants treated with adalimumab alone or in combination with topical agents.
Adalimumab
Adalimumab administered by subcutaneous injection.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Adalimumab
Adalimumab administered by subcutaneous injection.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The treating physician has decided to change the current treatment or add additional treatments for any reason including but not limited to inadequate response, intolerance, sub-optimal compliance or participant preference.
Exclusion Criteria
* Participant could not or would not sign informed consent.
* Presence of other condition that, in the opinion of the treating physician, prohibits the participant from participating in the study or obscured the assessment of the treatment of plaque psoriasis.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cato Research
INDUSTRY
JSS Medical Research Inc.
INDUSTRY
AbbVie (prior sponsor, Abbott)
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AbbVie Inc.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kirk Barber Research, CA /ID# 57722
Calgary, Alberta, Canada
Richmond Road Diagnostic Treat /ID# 70913
Calgary, Alberta, Canada
Institute for Skin Advancement /ID# 66782
Calgary, Alberta, Canada
Thomas Nakatsui P.C. /ID# 55080
Edmonton, Alberta, Canada
Alberta DermaSurgery Centre /ID# 75513
Edmonton, Alberta, Canada
Wellington Medical Clinic Ltd. /ID# 55083
Nanaimo, British Columbia, Canada
Percuro Clinical Research, Ltd /ID# 54563
Victoria, British Columbia, Canada
Jason Ronald Sneath Medical Co /ID# 138026
Brandon, Manitoba, Canada
Winnipeg Clinic, Manitoba, CA /ID# 56865
Winnipeg, Manitoba, Canada
Maritime Medical Reseach Cente /ID# 128775
Bathurst, New Brunswick, Canada
Dr. Irina Turchin PC Inc. /ID# 66029
Fredericton, New Brunswick, Canada
Dermatologue Inc. /ID# 76074
Moncton, New Brunswick, Canada
Douglas N. Keeling MD Dermatol /ID# 55098
Quispamsis, New Brunswick, Canada
Karma Clinical Trials /ID# 55101
St. John's, Newfoundland and Labrador, Canada
Nexus Clinical Research /ID# 56403
St. John's, Newfoundland and Labrador, Canada
Eastern Canada Cutaneous Resea /ID# 46353
Halifax, Nova Scotia, Canada
SimcoDerm Medical and Surgical /ID# 96915
Barrie, Ontario, Canada
Kingsway Clinical Research /ID# 97255
Etobicoke, Ontario, Canada
Giroux, Sudbury, CA /ID# 55128
Greater Sudbury, Ontario, Canada
Dermatrials Research /ID# 124138
Hamilton, Ontario, Canada
Dr. Wei Jing Loo Medicine Prof /ID# 127546
London, Ontario, Canada
Lynderm Research Inc. /ID# 63206
Markham, Ontario, Canada
Toronto Regional Wound Healing /ID# 55135
Mississauga, Ontario, Canada
Dr. Anna Hinek Medicine Prof /ID# 148305
Mississauga, Ontario, Canada
Oakville Derma and Laser, CA /ID# 55130
Oakville, Ontario, Canada
Dr. Melinda Gooderham Medicine /ID# 54566
Peterborough, Ontario, Canada
York Dermatology Center /ID# 127786
Richmond Hill, Ontario, Canada
Specialized Dermatology Inc. /ID# 64031
St. Catharines, Ontario, Canada
Lori Shapiro Medicine Prof Inc /ID# 55126
Thornhill, Ontario, Canada
Toronto Dermatology Centre /ID# 55127
Toronto, Ontario, Canada
Dr. Isabelle Delorme Inc. /ID# 57791
Drummondville, Quebec, Canada
Dre. Angelique Gagne-Henley /ID# 125204
Montreal, Quebec, Canada
Dr. Loukia-Maria Mitsos /ID# 124156
Pierrefonds, Quebec, Canada
Dermatologie Sima Inc. /ID# 54922
Verdun, Quebec, Canada
Dr. Beatrice Wang /ID# 63242
Westmount, Quebec, Canada
Royal Univ. Hosp, Saskatoon,CA /ID# 74613
Saskatoon, Saskatchewan, Canada
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P12-678
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.